SensDx

SensDx uses cookies to track visits to our website only, no personal information is collected. By continuing to use the site you are agreeing to our use of cookies.

Understood

Flu SensDx already on sale!

FluSensDx detects influenza viruses even at a very early stage of infection in the patient. It is a valuable source of medical information that provides a chance for effective implementation of therapy with neuraminidase

Precision result, test rapidity, ease of use

High Sensitivity

The Flu SensDx test has a high sensitivity, comparable to the RT-PCR reference method. As the only one on the market, unlike the so-called “lateral flow” tests, it enables the detection of influenza virus presence at a very early stage of infection, when the pathogen level measured by RT-PCR reaches 38 cq.

Simplicity and rapidity

The FluSensDx test is easy to use - the application guides the user step by step, which means that it can be done by anyone. No additional qualifications are required. The test result is obtained within 3-5 minutes.

Digital precision

The test analyses digital data, which allows for high reliability and continuous monitoring of the quality of the test. The result obtained in digital form can be printed out, sent to a selected recipient or archived in the system. Together with the result, the recipient receives a quality monitoring report of the test. How it works?

Our products

SensDx is working on the technology of ultra-sensitive electrodes, modified with biological molecules. The molecules on the electrode surface are selected by biotechnological methods. It allows you to identify unambiguously which bacteria or virus is the cause of infection or to determine the oncological marker, DNA or RNA.

Currently, works in the field of cardiology, oncology, urology and veterinary medicine are being carried out.

Available soon!

Multi SensDx - test for identification of upper respiratory tract infections causes

Multisensor is a rapid diagnostic test to identify the etiology of an upper respiratory tract infection that identifies more than one pathogen in a single sample. Proper diagnosis of the causes of the infection will allow for effective and precise therapy, which will reduce the unnecessary use of antibiotics in cases where the infection is viral.

News

Stefan Müllner, PhD joins the the SensDx SA Advisory Board

25/04/2019

Stefan Müllner, PhD – the long time CEO of the autoimmune diagnostic specialist Protagen AG, Dortmund, Germany, with strong industrial background from management and board positions in the pharma (Hoechst, Aventis), biotech (Maltagen, Phenion, BiotEx, SusTech) consumer products (Henkel) and venture capital industries (fundamenta Capital) and has joined the Advisory Board of SensDx SA.

First place for SensDx in the Future Diagnostic category at Roche Innovation Summit

20/06/2018

On 18th June 2018 SensDx Digital Diagnostics presented itself at the prestigious Roche Innovation Summit in Basel. Among 150 individually invited companies from MedTech industry, SensDx got into Top 4 winning the category of Future Diagnostics in this way.

SensDx at the meeting with the Polish goverment

29/03/2018

SensDx, as a beneficiary of the National Center for Research and Development projects, was invited to the ceremony approved The Constitution for Science by the Council of Ministers.

Proceed to archive

Vision

Our vision is to revolutionize medical diagnosis worldwide by providing effective, rapid and easy-to-use tests to detect pathogens causing specific diseases.

Mission

Our mission is to prevent the spreading of bacteria and viruses by detecting pathogens at an early stage of development.

Technology

The innovative solution combines a simple tool based on a fast, ultra-sensitive diagnostic test with a mobile application for easy result interpretation.

Tests

The test tools are placed inside specially-designed devices called Mobi (for individual patients) or Pro (for medical professionals)

Team

SensDX comprises of an interdisciplinary team of experts specialising in biotechnological, chemical, electrochemical and electronic sciences, IT, production automation and business, including IP protection, technology commercialisation, sales and marketing. We work in line with modern management methods, high quality standards and safety regulations.

Accomplishments

The dynamic growth of SensDx has been facilitated by funds obtained through a wide range of subsidies. While evaluating the SensDx applications, experts appreciated not only the technology, which will have a wide range of applications in telemedicine and diagnostics, but also the innovative functionality, huge commercialisation potential and business model, implemented consistently by SensDx.

Learn more